Coccia, Margherita
Collignon, Catherine
Hervé, Caroline
Chalon, Aurélie
Welsby, Iain
Detienne, Sophie
van Helden, Mary J.
Dutta, Sheetij
Genito, Christopher J.
Waters, Norman C.
Van Deun, Katrijn
Smilde, Age K.
van den Berg, Robert A.
Franco, David
Bourguignon, Patricia
Morel, Sandra
Garçon, Nathalie
Lambrecht, Bart N.
Goriely, Stanislas
van der Most, Robbert
Didierlaurent, Arnaud M.
Article History
Received: 10 November 2016
Revised: 7 July 2017
Accepted: 11 July 2017
First Online: 8 September 2017
Change Date: 21 March 2018
Change Type: Correction
Change Details: In this article, Fig. 2b was mislabelled. The second row was incorrectly labelled as “Mi<sub>MPL</sub> > Mi<sub>PBS</sub> and Mi<sub>QS</sub> ≈ M<sub>PBS</sub>” this has now been corrected to “Mi<sub>QS-21</sub> > Mi<sub>PBS</sub> and Mi<sub>MPL</sub> ≈ Mi<sub>PBS</sub>”. The third row was incorrectly labelled as “Mi<sub>QS21</sub> > Mi<sub>PBS</sub> and Mi<sub>MPL</sub> ≈ Mi<sub>PBS</sub>” this has now been corrected to “Mi<sub>MPL</sub> > Mi<sub>PBS</sub> and Mi<sub>QS-21</sub> ≈ Mi<sub>PBS</sub>”. These errors have now been corrected in the PDF and HTML versions of this article.
Competing interests
: All authors have declared the following interests: M.C., C.C., C.H., A.C., P.B., S.M., N.G., R.v.d.M., D.F., R.A.v.d.B., and A.M.D. are, or were at the time of the study, employees of the GSK group of companies. S.M., P.B., R.v.d.M., and A.M.D. own GSK stocks. S.G.’s laboratory received a Public-Private Partnership grant from GlaxoSmithKline Biologicals SA and the Walloon Region (ref. “SAPOVAC”). A.K.S. was partly employed by the Academic Medical Center (AMC) of the University of Amsterdam, which has an agreement with GlaxoSmithKline Biologicals S.A. C.J.G. was supported by an appointment to the Postgraduate Research Participation Program at the Walter Reed Army Institute of Research administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and MRMC. The other authors report no financial conflict of interest.